KR101394245B1 - 아이속사졸 유도체 및 이의 용도 - Google Patents

아이속사졸 유도체 및 이의 용도 Download PDF

Info

Publication number
KR101394245B1
KR101394245B1 KR1020060135390A KR20060135390A KR101394245B1 KR 101394245 B1 KR101394245 B1 KR 101394245B1 KR 1020060135390 A KR1020060135390 A KR 1020060135390A KR 20060135390 A KR20060135390 A KR 20060135390A KR 101394245 B1 KR101394245 B1 KR 101394245B1
Authority
KR
South Korea
Prior art keywords
isoxazole
carboxylic acid
furan
phenyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020060135390A
Other languages
English (en)
Korean (ko)
Other versions
KR20070072384A (ko
Inventor
조정우
최상락
황선관
조경철
배성진
곽현정
이소영
구태성
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Priority to US12/159,718 priority Critical patent/US7915297B2/en
Priority to ES06835537T priority patent/ES2436103T3/es
Priority to EP06835537.9A priority patent/EP1971600B1/en
Priority to PCT/KR2006/005837 priority patent/WO2007078113A1/en
Priority to JP2008548427A priority patent/JP5246499B2/ja
Publication of KR20070072384A publication Critical patent/KR20070072384A/ko
Application granted granted Critical
Publication of KR101394245B1 publication Critical patent/KR101394245B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020060135390A 2005-12-30 2006-12-27 아이속사졸 유도체 및 이의 용도 Expired - Fee Related KR101394245B1 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/159,718 US7915297B2 (en) 2005-12-30 2006-12-28 Isoxazole derivatives and use thereof
ES06835537T ES2436103T3 (es) 2005-12-30 2006-12-28 Derivados de isoxazol y uso de los mismos
EP06835537.9A EP1971600B1 (en) 2005-12-30 2006-12-28 Isoxazole derivatives and use thereof
PCT/KR2006/005837 WO2007078113A1 (en) 2005-12-30 2006-12-28 Isoxazole derivatives and use thereof
JP2008548427A JP5246499B2 (ja) 2005-12-30 2006-12-28 イソキサゾール誘導体及びその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050135247 2005-12-30
KR1020050135247 2005-12-30

Publications (2)

Publication Number Publication Date
KR20070072384A KR20070072384A (ko) 2007-07-04
KR101394245B1 true KR101394245B1 (ko) 2014-05-14

Family

ID=38507387

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060135390A Expired - Fee Related KR101394245B1 (ko) 2005-12-30 2006-12-27 아이속사졸 유도체 및 이의 용도

Country Status (6)

Country Link
US (1) US7915297B2 (enExample)
EP (1) EP1971600B1 (enExample)
JP (1) JP5246499B2 (enExample)
KR (1) KR101394245B1 (enExample)
ES (1) ES2436103T3 (enExample)
WO (1) WO2007078113A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201600089A1 (ru) 2006-01-27 2017-01-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Покрытые энтеросолюбильной оболочкой цистеамин и цистамин и их производные
JP5205274B2 (ja) * 2006-11-22 2013-06-05 日本農薬株式会社 新規なピラゾール誘導体、有害生物防除剤及びその使用方法
ES2379746T3 (es) * 2007-06-29 2012-05-03 Sk Biopharmaceuticals Co., Ltd. Composición farmacéutica para la prevención y el tratamiento de la restenosis que comprende los derivados del isoxazol
US12404304B1 (en) 2007-11-14 2025-09-02 Sierra Sciences, Llc Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
US8883827B2 (en) 2009-06-05 2014-11-11 Oslo University Hospital Hf Azole derivatives as WTN pathway inhibitors
JP5922031B2 (ja) * 2009-12-16 2016-05-24 ニューロポア セラピーズ，インコーポレイティド 化合物
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
JP2013544874A (ja) * 2010-12-08 2013-12-19 オスロ ユニヴァーシティー ホスピタル エイチエフ Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体
WO2013078376A2 (en) 2011-11-23 2013-05-30 The Board Of Regents Of The University Of Texas System Isoxazole treatments for diabetes
CA2915975A1 (en) * 2013-06-26 2014-12-31 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
EP3116870A1 (en) 2014-03-13 2017-01-18 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138909A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015196071A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
US9783510B2 (en) 2014-08-22 2017-10-10 Vanderbilt University Small molecule mediated transcriptional induction of E-cadherin
US9505729B2 (en) * 2014-08-22 2016-11-29 Vanderbilt University Isoxazole analogs as mediators of transcriptional induction of E-cadherin
CN109251894B (zh) 2014-11-25 2022-10-04 宾州研究基金会 人神经胶质细胞转化成用于大脑和脊髓修复的神经细胞的化学重编程
WO2016095205A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. Heteroaryl orexin receptor antagonists
WO2016105484A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) * 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (en) * 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016101118A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Amidoethyl azole orexin receptor antagonists
CA2993450C (en) 2015-07-24 2023-10-24 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
KR20180093882A (ko) 2015-10-06 2018-08-22 프로테오스타시스 테라퓨틱스, 인크. Cftr 조절용 화합물, 조성물, 및 방법
MX386698B (es) 2016-04-07 2025-03-19 Proteostasis Therapeutics Inc Atomos de silicona que contienen analogos de ivacaftor
EP3472156B1 (en) 2016-06-21 2023-06-07 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA3162888A1 (en) * 2019-11-25 2021-06-03 The Penn State Research Foundation Chemotherapy for glioma through neuronal conversion
KR102500978B1 (ko) * 2021-05-10 2023-02-17 조성은 이속사졸 유도체를 포함하는 탈모 완화 및 발모 촉진용 조성물
US20240294876A1 (en) * 2021-05-18 2024-09-05 University Of Southern California Methods for the expansion of human granulocyte-macrophage progenitors and applications thereof
CN115677608B (zh) * 2022-09-08 2024-06-07 复旦大学 苯并异噁唑-3-甲酰胺类化合物及其合成和应用
KR102787749B1 (ko) * 2022-12-29 2025-03-31 중앙대학교 산학협력단 비스이소옥사졸 화합물을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5201932A (en) * 1989-09-22 1993-04-13 Basf Aktiengesellschaft Carboxamides
JPH05279351A (ja) * 1992-01-17 1993-10-26 Bayer Ag イソオキサゾールカルボン酸誘導体
JPH0827130A (ja) * 1994-07-15 1996-01-30 Teikoku Hormone Mfg Co Ltd 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH475301A (de) * 1964-10-27 1969-07-15 Ciba Geigy Verfahren zur Herstellung von mit Oxazolverbindungen optisch aufgehellten Formkörpern
FR2073284B1 (enExample) * 1969-12-23 1973-07-13 Ferlux
BE795808A (fr) 1972-02-24 1973-08-22 Beecham Group Ltd Amidazoles polysubstitues
US3852293A (en) * 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
GB1492663A (en) 1975-02-20 1977-11-23 Lepetit Spa 4-amino-3-pyrrole carboxamides
JPS568352A (en) * 1979-07-03 1981-01-28 Shionogi & Co Ltd Aminoalkylvenzene derivative
JPS6143191A (ja) * 1984-08-07 1986-03-01 Kyorin Pharmaceut Co Ltd イミダゾ〔１，５−ａ〕ピリミジン誘導体
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
EP0766676B1 (en) 1994-06-24 2002-05-22 Euroceltique S.A. Compounds for inhibiting phosphodiesterase iv
EP0726263A3 (en) 1995-02-08 1996-10-09 American Cyanamid Co Herbicides (1,3,4) oxadiazoles and thiadiazoles
TWI262185B (en) * 1999-10-01 2006-09-21 Eisai Co Ltd Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
JP4052573B2 (ja) * 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用
US7244861B2 (en) * 2001-03-30 2007-07-17 Eisai Co., Ltd. Benzene compound and salt thereof
WO2002080899A1 (fr) * 2001-03-30 2002-10-17 Eisai Co., Ltd. Agent de traitement de maladie digestive
WO2002098840A1 (en) * 2001-06-04 2002-12-12 Eisai Co., Ltd. Carboxylic acid derivative and medicine comprising salt or ester of the same
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
AU2002342607B2 (en) * 2001-08-06 2006-10-19 Pharmacia Italia S.P.A. Aminoisoxazole derivatives active as kinase inhibitors
AR034897A1 (es) * 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
JPWO2003016265A1 (ja) * 2001-08-17 2004-12-02 エーザイ株式会社 環状化合物およびｐｐａｒアゴニスト
WO2004069805A1 (en) * 2003-02-10 2004-08-19 Bayer Healthcare Ag Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
JP2006176443A (ja) * 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
WO2008046072A2 (en) * 2006-10-13 2008-04-17 The Board Of Regents Of The University Of Texas System Chemical inducers of neurogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5201932A (en) * 1989-09-22 1993-04-13 Basf Aktiengesellschaft Carboxamides
JPH05279351A (ja) * 1992-01-17 1993-10-26 Bayer Ag イソオキサゾールカルボン酸誘導体
JPH0827130A (ja) * 1994-07-15 1996-01-30 Teikoku Hormone Mfg Co Ltd 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters(2000), Vol. 10, pp. 2047-2050 *
Bioorganic & Medicinal Chemistry Letters(2000), Vol. 10, pp. 2047-2050*

Also Published As

Publication number Publication date
WO2007078113A1 (en) 2007-07-12
ES2436103T3 (es) 2013-12-27
KR20070072384A (ko) 2007-07-04
EP1971600A4 (en) 2011-06-15
JP2009522255A (ja) 2009-06-11
JP5246499B2 (ja) 2013-07-24
US7915297B2 (en) 2011-03-29
EP1971600B1 (en) 2013-08-21
EP1971600A1 (en) 2008-09-24
US20090131336A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
KR101394245B1 (ko) 아이속사졸 유도체 및 이의 용도
CN114573575B (zh) 一类含氧五元杂环化合物、合成方法、药物组合物及用途
RU2260007C2 (ru) Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования
EP2509955B1 (en) Pyrazole derivatives as modulators of calcium release-activated calcium channel
JP5008569B2 (ja) Ｃ−ｆｍｓキナーゼのインヒビターとしての芳香族アミド
JP5408434B2 (ja) アミド化合物
CZ20013276A3 (cs) Nové amidové deriváty, způsob jejich přípravy a farmaceutická kompozice, která je obsahuje
AU2012304311A1 (en) Amido compounds as RORyt modulators and uses thereof
JP2009533410A (ja) Ｇタンパク質共役型受容体（ｇｐｒ１１９）アゴニストとしてのアゼチジン誘導体
JP2008545010A (ja) Ｇタンパク質共役受容体アゴニスト
CA2962917C (en) Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms)
CN110099900B (zh) 针对Smoothened突变株的刺猬通路抑制剂
KR20180073671A (ko) Gpr84에 대하여 작용 효과를 구비하는 화합물 및 이의 제조방법과 용도
JP2008530075A (ja) Ｈｍ７４ａ受容体アゴニストとしての２置換５員ヘテロアリールカルボキシレート
JP2016506939A (ja) 神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
JP2001261674A (ja) ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
US6627647B1 (en) Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
EP2382205A2 (fr) Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
TW200539872A (en) Therapeutic agents
Cai et al. Design, synthesis, and biological evaluation of benzofuran derivatives as ET receptor antagonists
KR102542698B1 (ko) 신규한 벤조사이오펜 유도체 및 bet 억제제로서의 용도
KR20090071679A (ko) 벤즈아미드 유도체를 포함하는 암 질환의 예방 및 치료용약학 조성물
JP2016508960A (ja) Ｋｃｎｑ２／３モジュレーターとしての特定のカルボキサミド
US20070149600A1 (en) Substituted octahydroisoindoles
WO2006062110A1 (ja) ピペラジン誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170106

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180130

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190227

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210508

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210508